Physician profile
Iva Minga
NPI 1104357466
$1,035.26
in general payments reported to CMS, 2019-2025
14 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $335 · 2023: $111 · 2024: $21.17 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $206.40 | 2024-2025 | Pascal, Evoque |
| Novartis Pharmaceuticals Corporation | $169.42 | 2021-2023 | |
| Abbott Laboratories | $135.46 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.06 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $116.78 | 2025 | Opsumit, Uptravi |
| Abiomed | $97.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.05 | 2023 | Farxiga, Brilinta |
| Amgen INC. | $35.08 | 2021-2025 | Repatha |
| Cvrx, INC. | $26.06 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $21.25 | 2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $20.67 | 2023 | Definity |
| Lilly USA, LLC | $18.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2022 | |
| Esperion Therapeutics, INC. | $14.00 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iva Minga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.